| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
[Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.
|
Br J Pharmacol
|
2002
|
1.14
|
|
2
|
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies.
|
J Pharmacol Exp Ther
|
2007
|
1.09
|
|
3
|
In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S.
|
J Pharmacol Exp Ther
|
2008
|
1.05
|
|
4
|
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor.
|
Peptides
|
2007
|
0.93
|
|
5
|
[Arg(14),Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies.
|
J Pharmacol Exp Ther
|
2002
|
0.89
|
|
6
|
Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice.
|
Peptides
|
2007
|
0.87
|
|
7
|
Ascorbic and 6-Br-ascorbic acid conjugates as a tool to increase the therapeutic effects of potentially central active drugs.
|
Eur J Pharm Sci
|
2004
|
0.84
|
|
8
|
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor.
|
J Pharmacol Exp Ther
|
2004
|
0.83
|
|
9
|
Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice.
|
Br J Pharmacol
|
2002
|
0.82
|
|
10
|
Nociceptin/orphanin FQ receptor knockout rats: in vitro and in vivo studies.
|
Neuropharmacology
|
2010
|
0.80
|
|
11
|
Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120.
|
Peptides
|
2008
|
0.78
|
|
12
|
Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)NH2 analogues. 2. In vivo studies.
|
Naunyn Schmiedebergs Arch Pharmacol
|
2002
|
0.76
|
|
13
|
Anti-inflammatory and analgesic effects displayed by peptides derived from PKI55 protein, an endogenous protein kinase C inhibitor.
|
Naunyn Schmiedebergs Arch Pharmacol
|
2010
|
0.75
|